Generics 18

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Apremilast manufacturers

18 products found

Filters

18 products found

apremilast

Tablets, film coated 10 mg, 20 mg, 30 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Comments
EU MA's Running
Manufacturer #21467

Manufacturer usually replies in 4 days

apremilast

Tablets, film coated 10mg, 20mg, 30mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #337
A pharmaceutical manufacturer based in the EU that has been active in 90+ countries selling its products in the EU, Africa, North America, Middle East, and Asia for 30+ years. Key production lines are Rx and OTC. Main therapeutic areas include diabetes, CNS, and dermatology. The company's production lines are GMP-compliant. The company possesses branches in the Middle East and Asia.

Manufacturer usually replies in 5 days

apremilast

Tablets, film coated 10 mg, 20 mg, 30 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #17047
A pharmaceutical manufacturer based in the EU that sells its products in Europe, the Middle East, CIS, LATAM, and Asia. Key production lines are pharmaceuticals, bio and nanopharmaceuticals, medical devices, and nutraceuticals. The main therapeutic area is oncology.

Manufacturer usually replies in 10 days

apremilast

Tablets, film coated 10 mg, 20 mg, 30 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #260
Pharmaceutical manufacturer operating in the EU for 50+ years. Activities include scientific development, manufacturing, out-licensing, marketing, and distribution of high-quality generic medicines. The company owns several production facilities that all comply with EU GMP requirements. Key dosage forms include conventional solids, cytostatic injectables, and cytostatic orals. The company holds an in-house R&D and Intellectual property business unit, as well as a regulatory affairs team that prepares CTD dossiers and maintains direct contact with regulatory agencies worldwide. The portfolio includes more than three thousand MA sets approved in the EU while hundreds of MA are in progress. Key therapy lines are cardiovascular, CNS, diabetes, immunology, oncology, and more. The company is active in nearly 100 countries worldwide, selling its products in Africa, Asia, Australia, Europe, LATAM, and the Middle East.

Manufacturer usually replies in 12 days

apremilast

Tablets, film coated 10 mg, 20 mg, 30 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
Iceland
GMP approvals
EU GMP
Manufacturer #28915

Manufacturer usually replies in 16 days

apremilast

Oral suspension 5 mg/ml

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #31060

Manufacturer usually replies in nan days

apremilast

Tablets, film coated 10 mg, 20 mg, 30 mg

Dossier type
US CTD
Dossier status
Ready to file
Country of origin
Canada
GMP approvals
FDA, Canada
Comments
Reference product : Otezla (Celgene)
Manufacturer #278

The company has become a prominent partner of the pharmacy community in North America, with the fastest rising market share among generic leaders. It can provide best-in-class supply reliability thanks to production capacity. In more than 50 countries, it's available locally or through corporate partnerships. R&D expenditures range from $40 million to $50 million per year. They are dedicated to maintaining a customer satisfaction rate of over 95% by continuously enhancing supply chain efficiency.

Manufacturer usually replies in 7 days

apremilast

Tablets 10 mg, 20 mg, 30 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Manufacturer #15189
The company, which was founded in 1989, is involved in developing, manufacturing, and distributing a wide range of formulations for anti-infectives, cardiovascular, anti-diabetic, dermatological, and hormone treatment. The corporation has a global presence in 170 + countries, 60+ WHO-prequalified medications, and 3700+ product registrations.

Manufacturer usually replies in 9 days

apremilast

Tablets, film coated 30 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Manufacturer #1338

Manufacturer usually replies in 7 days

apremilast

Tablets, film coated 10 mg, 20 mg, 30 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
Chile , Panama
Available for
Licensing with supply
Manufacturer #261
A pharmaceutical manufacturer based in the EU that has been selling its products in Europe for 20+ years. Main therapeutic areas include diabetes, CNL, dermatology, and oncology. Main dosage forms include solid and liquid oral, sterile dosage forms, and ointments. The company possesses 10+ manufacturing facilities that are cGMP-compliant.

Manufacturer usually replies in 6 days

apremilast

Tablets, film coated 10mg, 20mg, 30mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
India
GMP approvals
EU GMP
Available for
Licensing with supply, Distribution only
Comments
Interested in projects only for European markets.
Manufacturer #15224

Manufacturer usually replies in 7 days

apremilast

Tablets 10 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19152

Manufacturer usually replies in 2 days

apremilast

Tablets 10mg, 20mg, 30mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
India
GMP approvals
EU GMP
Manufacturer #10897
A pharmaceutical manufacturer based in Asia that is active in 80+ countries selling its products in Europe, North America, Africa, the Middle East, CIS, LATAM, and Asia for 40+ years. The company's production lines are WHO GMP-compliant. The main dosage forms are tablets, capsules, dry syrups, suspensions, and injections. The main therapeutic areas include antifungal, analgesics, and psychotropics.

Manufacturer usually replies in 12 days

apremilast

Tablets, film coated 10 mg, 20 mg, 30 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
Turkey
GMP approvals
PICS
Manufacturer #13510
It was established in the 2010s. It creates and sells biotech products developed with natural product extracts, helping to improve your heart health, immune system, or mood. It offers the pharmaceutical and nutraceutical industry a natural, science-based therapeutic alternative that can be safely used either in combination with existing medications as add-on ingredients for improved efficacy or presented as a single standing remedy; with patented products, proven benefits, and claims for our natural ingredients in the areas of for example mood improvement, anxiety and stress reduction, eye-health, cardiovascular health advancement and enhancement of the body´s immune system against cold and flu.

Manufacturer usually replies in 6 days

apremilast

Tablets, film coated 10mg, 20mg, 30mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Argentina
GMP approvals
Argentina
Manufacturer #16199
One of the largest and biggest names in the pharmaceutical industry. The company has a network all across the globe. They are known to be partnering with similar companies for a very long time.

Manufacturer usually replies in 9 days

apremilast

Tablets, immediate release (IR) 10 mg, 20 mg, 30 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
India
GMP approvals
FDA, EU GMP, WHO
Manufacturer #16394

Manufacturer usually replies in 13 days

apremilast

Tablets 10 mg, 20 mg , 30 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Turkey
GMP approvals
PICS
Manufacturer #13095

Manufacturer usually replies in 5 days

apremilast

Tablets, immediate release (IR) 10 mg, 20 mg, 30 mg

Dossier type
US CTD
Dossier status
Under development
Country of origin
India
GMP approvals
FDA, Canada
Manufacturer #16394

Manufacturer usually replies in 13 days

Apremilast:

Apremilast, also commonly known under the popular brand name of Otezla, is a medication used in the treatment of certain types of psoriasis and psoriatic arthritis. As well as also being effective in therapies for certain other immune system-related inflammatory diseases. In both the United States of America and the European Union, apremilast alone or in combination with disease-modifying antirheumatic drugs is indicated for active psoriatic arthritis, for which it is predominantly prescribed. Originally patented by a pharmaceutical products company, apremilast manufacturers and apremilast suppliers have since gained it regulatory approval by the FDA in 2014 and by the European Union in 2015 for use in this treatment. Currently, apremilast has also been approved for use in treating oral ulcers associated with Bechet’s disease and can be found produced by manufacturers for sale on the global marketplace. Where it is frequently on the wholesale pharmaceutical products list of distributors, being available for order at a variety of cost and price points.

Method of action of apremilast:

Apremilast belongs to a group of drugs which serves as phosphodiesterase 4 inhibitors. Although the full mechanism of action is still not fully established, it is thought to function through the phosphodiesterase 4 mediated disruption of cyclic adenosine monophosphate. This increases cyclic adenosine monophosphate intracellular levels, resulting in the suppression of inflammation by decreasing the expression of TNF-α, IL-17, IL-23, and other inflammatory mediators. Which are reasonable for symptomatic inflammatory effects such as mouth ulcers, skin lesions, and arthritis. Therefore, the administration of apremilast culminates in a cascade which leads to a decrease in of the above mediators, relieving inflammatory symptoms.

Form and dosage of apremilast:

The final form and packaging of apremilast is dependent on the manufacturers and suppliers, as well as the specific order and distributors. However, apremilast predominantly comes in tablet and film-coated tablet form, which is taken orally. It is a prescription medication, as such, it can only be taken with the approval of a healthcare professional. The typical dosage defers to the opinion of the prescribing professional and is dependent on the particular individual and underlying condition being treated. Caution is advised by manufacturers in patients that have a history of psychiatric illness, as use has a probability of causing psychiatric symptoms and drastic weight loss.

Apremilast on Pipelinepharma:

Currently, at the time of writing, we have found 10 verified apremilast manufacturers and apremilast suppliers from our online global list of B2B sellers. These manufacturers, suppliers, and distributors have apremilast available for wholesale order and are located in various countries including India, Canada, the European Union, and Argentina. Each company listed on our online marketplace has been verified by the Pipelinepharma team according to strict quality control. This ensures the reputability of the seller and limits buyer mileage, making for an easier transaction experience for all B2B parties.

Price of Apremilast and how to buy:

The typical price of apremilast is dependent on numerous factors including organisation, market, and quantity. However, a cursory search online reveals an approximate cost for wholesale apremilast is priced at USD 716.71 for 56×30 mg tablets. These values are for sale to the UK’s national health service, as such, they serve only as approximations for the current market situation. Although the prices on the B2B wholesale Pipelinepharma marketplace remain confidential between both B2B parties, the seller may choose to list a desired price to facilitate the online transaction. If so, an ‘Accept’ and ‘Negotiate’ button will be displayed through the online interface, with a ‘Get offer’ button being shown in the absence.